NCT07135050View on ClinicalTrials.gov

Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

March 31, 2029

Study Completion Date

July 31, 2029

Conditions
Pitt Hopkins Syndrome
Interventions
GENETIC

MZ-1866

AAV-9 gene therapy delivered by intracerebroventricular injection

Sponsors

Lead Sponsor

Mahzi Therapeutics
All Listed Sponsors
lead

Mahzi Therapeutics

INDUSTRY

NCT07135050 - Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome | Biotech Hunter | Biotech Hunter